- Home
- ABUS vs GSHD Comparison
ABUS vs GSHD Comparison
Compare ABUS & GSHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABUS | GSHD |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.6M | 1.0B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ABUS | GSHD |
|---|---|---|
| Price | $4.13 | $48.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $5.00 | ★ $72.17 |
| AVG Volume (30 Days) | ★ 1.6M | 391.2K |
| Earning Date | 05-13-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | N/A | ★ 1.04 |
| Revenue | $14,083,000.00 | ★ $365,304,000.00 |
| Revenue This Year | N/A | $16.40 |
| Revenue Next Year | $239.71 | $18.53 |
| P/E Ratio | ★ N/A | $48.07 |
| Revenue Growth | ★ 128.21 | 16.15 |
| 52 Week Low | $3.04 | $39.64 |
| 52 Week High | $5.10 | $114.76 |
Technical Indicators
Market Signals| Indicator | ABUS | GSHD |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 57.97 |
| Support Level | $3.41 | $39.99 |
| Resistance Level | $4.71 | $77.70 |
| Average True Range (ATR) | 0.20 | 2.60 |
| MACD | -0.03 | 1.09 |
| Stochastic Oscillator | 13.57 | 56.24 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.